Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...
As a biotech that's planning to go big on artificial intelligence (AI) for drug development, Recursion Pharmaceuticals (NASDAQ: RXRX) is a decidedly forward-thinking organization. Rather than simply ...
Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...
Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...
Hosted on MSN
Is Recursion Pharmaceuticals a Millionaire Maker?
Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results